Dexniguldipine hydrochloride

Drugs of the Future

Volumn 22, Issue 2, 1997, Pages 114-122

  Robinson, K A ^a   Robinson, C P ^a   Castaner J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZIDOPINE; CALCIUM CHANNEL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DEXNIGULDIPINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; NIGULDIPINE; PACLITAXEL; RHODAMINE 123; VERAPAMIL; VINBLASTINE; VINCRISTINE;

CANCER; CELL CULTURE; DIURESIS; DOSE RESPONSE; DRUG BINDING; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HYPOCALCEMIA; HYPOTENSION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; SHORT SURVEY; TUMOR CELL; VOMITING;

EID: 0030951439     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.02.393107     Document Type: Short Survey

References (67)

1. Amschler, H., Flockerzi, D., Klemm, K. et al. (Byk Gulden Lomberg Chem. Fabrik GmbH). 1,4-Dihydropyridine enantiomers. AU 8816264, EP 296316, EP 343193, WO 8807525.
2. Klemm, K., Ulrich, W.-R., Flockerzi, D., Sanders, K., Beller, K.-D. (Gyk Gulden Lomberg Chem. Fabrik GmbH). Optically pure (R)-(-)-niguldipine and its derivs. for treating tumor diseases. WO 8907443.
3. Biedler, J.L., Riehm, H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross resistance, radioautographic and cytogenetic studies. Cancer Res 1970, 30: 1174-84.
4. Gros, P., Croop, J., Roninson, I., Varshavasky, A., Houseman, D. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci USA 1986, 83: 337-41.
5. Goldstein, L.J., Galski, H., Fojo, A. et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81: 116-24.
6. Bradley, G., Jurunka, P.F., Ling, V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988, 948: 87-128.
7. Deffie, A.M., Alam, T., Seneviratne, C., Beenken, S.W., Batra, J.K., Shea, T.C., Henner, W.D., Goldenberg, G.J. Multifactorial resistance to adriamycin: Relationship of DNA repair, glutathione-S-transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res 1988, 48: 3595-602.
8. Whelan, R.D.H., Waring, C.J., Wolf, C.R., Hyes, J.D., Hosking, L.K., Hill, B.T. Over-expression of P-glycoprotein and glutathione S-transferase PI in MCF-7 cells selected for vincristine resistance in vitro. Cancer Commun 1989, 1: 359-65.
9. Isabella, P., Capranico, G., Zunino, F. The role of topoisomerase II in drug resistance. Life Sci 1991, 48: 2195-205.
10. Gekeler, V., Frese, G., Noller, A. et al. MDR1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state of adult and childhood leukaemias. Brit J Cancer 1992, 66: 507-17.
11. Mattern, J., Volm, M. Multiple pathway drug resistance. Int J Oncol 1993, 2: 557-61.
12. Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41: 1967-72.
13. Willingham, M.C., Cornwell, M.M., Cardareli, C.O., Gottesman, M.M., Pastan, I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive B cells: Effects of verapamil and other drugs. Cancer Res 1986, 46: 5941-6.
14. Safa, A.R., Glover, C.J., Sewell, J.L., Meyers, M.B., Biedler, J.L., Felsted, R.L. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987, 262: 7884-8.
15. Kessel, D. Effects of phorbol esters and doxorubicin transport systems. Biochem Pharmacol 1987, 37: 2297-9.
16. Fine, R.L., Patel, J., Chabner, B.A. Phorbol esters induced multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988, 85: 582-6.
17. O'Brian, C.A., Fan, D., Walrd, N.E., Seid, C., Fidler, I.J. Level of protein kinase C activity correlated directly with resistance to adriamycin in murine fibrosarcoma cell. FEBS Lett 1989, 246: 78-82.
18. Yu, G., Ahmad, S., Aquino, A., Fairchild, C.R., Trepel, J.B., Ohno, S., Suzuki, K., Tsuruo, T., Cowan, K.H., Glazer, R.I. Transfection with protein kinase Calpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 1991, 3: 181-9.
19. Chambers, T.C., Zheng, B., Kuo, J.F. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 1992, 41: 1008-15.
20. Hofmann, J., Wolf, A., Spitaler, M., Böck, G., Drach, J., Ludescher, C., Grunicke, H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 1992, 118: 361-6.
21. Thierry, A.R., Dritschilo, A., Rahman, A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun 1992, 187: 1098-105.
22. Hofmann, J., Uberall, F., Egle, A., Grunicke, H. B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. Int J Cancer 1991, 47: 870-4.
23. Reymann, A., Looft, G., Woermann, C., Dietel, M., Erttmann, R. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCI. Cancer Chemother Pharmacol 1993, 32: 25-30.
24. Roller, E., Klumpp, B., Krause, J., Eichelbaum, M., Schumacher, K. Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines. Cancer Chemother Pharmacol 1993, 32: 151-5.
25. Hill, B.T., Hosking, L.K. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance. Cancer Chemother Pharmacol 1994, 33: 317-24.
26. 1-adrenoreceptors. Eur J Pharmacol 1989, 172: 131-46.
27. Ozols, R.F., Cunnion, R.E., Klecker, R.W. Jr., Hamilton, T.C., Ostchega, Y., Parillo, J.E., Young, R.C. Verapamil and adriamycin in the treatment of drug resistant ovarian cancer patients. J Clin Oncol 1987, 5: 641-7.
28. Karck, U., Rathgeb, F., Wurst, W., Meerpohl, H.G. Open phase I/II study of standard FEC therapy with B8509-35, a novel drug blocking the P-170 glycoprotein. 7th NCI-EORTC Symp New Drugs Cancer Chemother (March 17-20, Amsterdam) 1992, Abst 085.
29. Malkhandi, P.J., Ferry, D.R., Boer, R., Kerr, D.J. P-Glycoprotein has a drug acceptor site for 1,4-dihydropyridines which is localised on an intracellular domain. Proc Amer Assoc Cancer Res 1995, 36: Abst 1977.
30. 3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 1994, 288: 105-14.
31. Überall, F., Maly, K., Egle, A., Doppler, W., Hofmann, J., Grunicke, H.H. Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res 1991, 51: 5821-5.
32. Gietzen, K., Abdallah, F., Bai, G. Selective Inhibition of proliferation by a novel dihydropyridine derivative with anti-calmodulin activity in the mammal tumor cell line ZR-75-1. Med Sci Res 1990, 18: 627-9.
33. Gietzen, K., Abdallah, F., Bai, G. Inhibition of tumour cell growth by a novel dihydropyridine derivative. Eur J Cancer 1990, 26: 922.
34. ++/calmodulin. Cancer Res 1990, 50: 1645-9.
35. Fiebig, H.H., Berger, D.P., Dengler, W., Licht, T., Winterhalter, B., Wallbrecher, E., Sanders, K.H. B859-35, a new anticancer drug with MDR reversing properties. Ann Oncol 1992, 3(Suppl. 1): 052.
36. Gekeler, V., Wilisch, A., Engelcke, M., Probst, G., Hofmann, J., Neumann, M., Probst, H. Effects of the new PKC inhibitor dexniguldipine-HCI (B8509-035), an enantiomeric pure dihydropyridine, on DNA-replication and cell cycle. Proc Amer Assoc Cancer Res 1993, 34: Abst 2439.
37. Ukena, D., Boewer, C., Oldenkott, B., Rathbeg, F., Wurst, W., Zech, K., Sybrecht, G.W. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCI after oral administration: A phase I dose-escalation trial. Cancer Chemother Pharmacol 1995, 36: 160-4.
38. Beck, J., Gekeler, V., Ringger, M., Handgretinger, R., Neithammer, D. Rhodamine-123 efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies. Cancer Lett 1996, 99: 197-207.
39. Hofmann, J., Gekeler, V., Ise, W., Noller, A., Mitterdorfer, J., Hofer, S., Utz, I., Gotwald, M., Boer, R., Glossman, H. Mechanism of action of dexniguldipine-HCI (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol 1995, 49: 603-9.
40. Schuller, H.M., Orloff, M., Reznik, G.K. Inhibition of protein-kinase-C-dependent cell proliferation of human lung cancer cell lines by the dihydropyridine dexniguldipine. J Cancer Res Clin Oncol 1994, 120: 354-8.
41. 3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 1995, 49: 1851-61.
42. Chan, D., Chuang, N., Jewett, P., Kirpotin, D., Helfrich, B., Bunn, P. Jr. Reversal of multidrug resistance by dexniguldipine (B8509-035), niguldipine and verapamil in small cell lung carcinoma cell lines. Proc Amer Assoc Cancer Res 1993, 34: Abst 1923.
43. Schuller, H.M., Miller, M.S., Reznik, G.K. Antiproliferative effects of dihydropyridines on human lung cancer cell lines. Proc Amer Assoc Cancer Res 1993, 34: Abst 2069.
44. Chan, D., Sobolevsky, S., Kirpotin, D., Helfrich, B., Helm, K., Bunn, P. Effects of dexniguldipine, verapamil, and cyclosporin A on multidrug resistance in aerodigestive cancers. Proc Amer Assoc Cancer Res 1994, 35: Abst 2113.
45. Ise, W., Hogg, M., Sanders, K.-H., Gekeler, V. Reversal of resistance to taxol and taxotere by dexniguldipine-HCI: Dose dependent modulation in various human MDR cell lines. Proc Amer Assoc Cancer Res 1994, 35: Abst 2123.
46. Tang, Y., Qin, Y., Schally, A., Beckman, B. Dexniguldipine hydrochloride, a protein kinase C-specific inhibitor, suppresses in vitro growth of human pancreatic and colon cancer cells. Proc Amer Assoc Cancer Res 1995, 36: Abst 2598.
47. Roller, E., Klumpp, B., Schumacher, K. Analysis of the MDR phenotype and resistance circumvention with dexniguldipine or dexverapamil in human cell lines. Ann Oncol 1994, 5(Suppl. 5): Abst 314.
48. Schroder, J., Esteban, M., Muller, M.R., Kasimir-Bauer, S., Bamberger, U., Heckel, A., Seeber, S., Scheulen, M.E. Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo. J Cancer Res Clin Oncol 1996, 122: 307-12.
49. Dietel, M., Herzig, I., Reymann, A., Brandt, I., Schaefer, B., Bunge, A., Heidebrecht, H.J., Seidel, A. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA. J Cancer Res Clin Oncol 1994, 120: 263-71.
50. Boer, R., Haas, S., Schodl, A. Influence of dexniguldipine-HCI on rhodamine 123 accumulation in a multidrug-resistant leukaemia cell line: Comparison with other chemosensitisers. Eur J Cancer 1994, 30A: 1117-23.
51. Borchers, C., Ulrich, W.R., Klemm, K., Ise, W., Gekeler, V., Haas, S., Schodl, A., Conrad, J., Przybylski, M., Boer, R. B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCI, photolabels P-glycoprotein. Mol Pharmacol 1995, 48: 21-9.
52. Borchers, C., Boer, R., Denzinger, T., Ulrich, W.-R., Gekeler, V., Ise, W., Klemm, K., Przybylski, M. Localization of the dexniguldipine binding site of P-glycoprotein in multidrug resistant cancer cells by photoaffinity labeling and mass spectrometry. Proc Amer Assoc Cancer Res 1996, 37: Abst 2234.
53. Patterson, K.K., Beckman, B.S., Mallia, C.M., Jeter, J.R. Jr. Dexniguldipine hydrochloride, a PKC-specific inhibitor, affects FELC proliferation and differentiation. Proc Amer Assoc Cancer Res 1994, 35: Abst 460.
54. Ise, W., Gekeler, V., Spitaler, M., Hofmann, J., Utz, I., Grunicke, H., Mitterdorfer, J., Sanders, K. Mechanism of action of the new potent multidrug resistance modulator dexniguldipine-HCI (B8509-035). Ann Oncol 1994, 5(Suppl. 5): Abst 313.
55. Neumann, M., Wilisch, A., Didens, H., Probst, H., Gekeler, V. MDR hamster cells exhibiting multiple altered gene expression: Effects of dexniguldipine-HCI (B859-35), cyclosporin A and buthionine sulfoximine. Anticancer Res 1992, 12: 2297-302.
56. Reymann, A., Seidel, A., Erttmann, R., Woermann, C., Dietel, M. Interaction in cellular kinetics of cyclosporin A and dexniguldipine-HCI in multidrug resistant mouse leukemia cells. Proc Amer Assoc Cancer Res 1994, 35: Abst 2107.
57. Reymann, A., Heidebrecht, H.-J., Herzig, I., Erttmann, R., Looft, G., Woermann, C., Dietel, M. The MDR modulator dexniguldipine-HCI (B859-35) is exported from multidrug resistant mouse leukemia cells. Proc Amer Assoc Cancer Res 1993, 34: Abst 1906.
58. VandeVrie, W., Schellens, J.H.M., Loos, W.J., Kolker, H.J., Verwey, J., Stoter, G., Durante, N.M.C., Eggermont, A.M.M. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. Cancer Res Clin Oncol 1996, 122: 403-8.
59. Boven, E., Jansen, W., Van Tellingen, O., Beijnen, J., Pinedo, H. Modulation of vincristine (VCR) concentrations by dexniguldipine or BIBW22BS in tissues of tumor-bearing nude mice. Proc Amer Assoc Cancer Res 1995, 36: Abst 2031.
60. Nussler, V., Pelka-Fleischer, R., Zwierzina, H., Nerl, C., Beckert, B., Gullis, E., Gieseler, F., Bock, S., Bartl, R., Petrides, P.E. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - First experience with their reversal. Ann Hematol 1994, 69(Suppl. 1): S25-9.
61. Mross, K., Mayer, U., Wörmann, B., Hanauske, A.R., Lehmann, M., Hossfeld, D.K. Pharmacokinetics and toxicity of dexniguldipine after single and repetitive daily 4 h infusions in cancer patients. Anti-Cancer Drugs 1994, 5(Suppl. 1): Abst 104.
62. Scheulen, M.E., Nüssler, V., Lehmann, M. Phase I study of dexniguldipine in combination with vinblastine to determine the MTD of dexniguldipine alone and in combination with vinblastine. Anti-Cancer Drugs 1994, 5(Suppl. 1): Abst 103.
63. Scheulen, M.E., Nüssler, V.A., Kriegmair, M. et al. Phase I study of i.v. dexniguldipine plus vinblastine. Proc Amer Soc Clin Oncol 1994, 13: Abst 419.
64. Panella, T.J., Costanzi, J.J., Rathgeb, F., Schuller, H., Bunn, P.A. A phase I trial of oral dexniguldipine (B8509-035) (dNIG) in patients with refractory solid tumors. Proc Amer Soc Clin Oncol 1993, 12: Abst 404.
65. Scheulen, M.E., Meusers, P., Schröder, J., Uppenkamp, M., Muller, M., Reiter, W.W., Weimar, C., Rathbeg, F., Brittinger, G., Seeber, S. Phase I/II trial of additive dexniguldipine (hADM) in acute myeloid leukemia (AML) refractory to previous daunorubicin and high-dose cytarabine (hAD). Proc Amer Assoc Cancer Res 1995, 36: Abst 1206.
66. Reiter, W.W., Ludescher, C., Wormann, B., Nüssler, V., Gattringer, C., Reiber, C., Weimar, C., Nowrousian, M.R., Thaler, J. A phase II trial with dexniguldipine, a new multidrug resistance modulator, in combination with VAD or VECD in patients with refractory myeloma. Ann Oncol 1994, 5(Suppl. 5): Abst 352.
67. Gehling, U., Weimar, C., Schuler, U., Rathgeb, F., Ehninger, G., Schumacher, K., Havemann, K. Phase I/II study of dexniguldipine and doxorubicine in advanced renal cell carcinoma (RCC). FASEB J 1995, 9(3, Part 1): Abst 560.